<DOC>
	<DOCNO>NCT00367640</DOCNO>
	<brief_summary>To evaluate safety efficacy SLIT compare placebo reduction symptom rescue medication usage</brief_summary>
	<brief_title>Safety Efficacy Sublingual Immunotherapy ( SLIT ) Tablets Grass Pollen Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Written consent Grasspollen relate allergic rhinoconjunctivitis least last 2 pollen season . Sensitised grass pollen ( positive SPT RAST level least class 2 ) . Total symptom score RRTSS previous pollen season great equal 12 . Safety laboratory resuts within reference range Pregnancy , breastfeeding/lactation Had receive desensitisation treatment grass pollen Treatment immunotherapy another allergen within previous 5 year Usual contraindication immunotherapy serious immunopathologic condition malignancy Treated betablockers continuous corticotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Sublingual immunotherapy</keyword>
	<keyword>Grass pollen tablet</keyword>
	<keyword>Allergic rhinoconjunctivitis</keyword>
</DOC>